Aligos Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Aligos Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to elect directors, ratify auditor, and vote on ESPP amendment and executive compensation.
NASDAQ
DEFA14A: Aligos Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Proposes Key Amendments
Aligos Therapeutics will hold its annual stockholders meeting on June 25, 2025, featuring proposals for director elections, auditor ratification, and amendments to stock plans and authorized shares.
NASDAQ
Aligos Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of Ernst & Young LLP as its independent accounting firm, and approve amendments to its incentive plan and corporate charter.
NASDAQ
DEFA14A: Aligos Therapeutics to Hold Annual Stockholders Meeting on June 27, 2024, to Vote on Key Proposals
Aligos Therapeutics is holding its annual stockholders meeting on June 27, 2024, to vote on proposals including the election of directors, ratification of the auditor, a potential reverse stock split, and amendments to the company's certificate of incorporation and 2020 Plan.
NASDAQ
Aligos Therapeutics is asking stockholders to approve a reverse stock split, an increase in authorized shares, and an amendment to its incentive award plan at the upcoming annual meeting.